TGTX

``` The deep research logic is organized as follows: Okay, let's tackle the user's query about TGTX. First, I need to gather all the relevant data from the provided references. The user is asking for an analysis of TG Therapeutics, so I'll start by checking the stock price and technical indicators. Looking at the references, the closing price on 2025-08-01 is $35.02 with a slight drop of 1.35% . The resistance level is $39.73 and support at $35.10 . The MACD is negative (-0.6), RSI is 31.62, and KDJ is 10.78 . The moving averages show the stock is below the 5-day (35.62), 10-day (36.39), and 20-day (37.05) averages . Next, the technical analysis from TradingView mentions a neutral rating with a buy signal for the 1-month period . The company is scheduled to report Q2 earnings on August 4th, with a consensus EPS of $0.29 and revenue of $146.27M . Analysts are cautiously optimistic, with a potential upside if they beat estimates . The stock's valuation metrics include a P/E of 142.01, P/S of 14.39, and a price-to-book ratio of 23.43 . The institutional ownership is 62.35% , and the debt-to-equity ratio is 1.03% with $276.24M in cash . Recent news highlights strong Briumvi sales growth and a potential Phase 1 trial for a new CAR T therapy . The user's profile shows interest in the NASDAQ Composite, suggesting a preference for blue-chip stocks and a short to medium-term horizon. They might be looking for a balance between technical signals and fundamental strength. Putting it all together, TGTX has mixed technicals (neutral to bearish) but strong fundamentals with upcoming earnings and product pipeline developments. The stock is undervalued relative to peers but faces competition from Roche's Ocrevus . The conclusion should reflect this balance, advising a hold with a bullish bias if technicals improve. ``` ### 🎯 **Conclusion** **TG Therapeutics (TGTX)** presents a **neutral-to-bullish** outlook with **mixed technical signals** and **strong fundamental momentum**. The stock is **below key moving averages**, **oversold** (RSI = 31.62), and faces **immediate resistance** at $39.73, but **analysts remain cautiously optimistic** with a **$40.50 average price target** and **Buy consensus**. Recent **Q2 earnings setup** and **Briumvi pipeline progress** highlight resilience, but **competition from Roche’s Ocrevus** and **valuation risks** pose headwinds. **Hold** for now, with a **bullish bias** if technicals confirm breakout above $39.73 resistance. --- ### 📊 **Technical Analysis** #### **Current Price vs. Moving Averages** | Metric | Value | Implication | |------------------------|-------------|--------------------------------------| | Last Price | $35.02 | Below 5-day (35.62), 10-day (36.39), 20-day (37.05) | | Resistance Level | $39.73 | Immediate upside target | | Support Level | $35.10 | Key floor if downside pressure | | Magic Signal | Neutral | No clear trend signal | |code|Ticker|Name|Date|Closing Price|market_code| |---|---|---|---|---|---| |TGTX|TGTX.O|Tg Therapeutics|20250801|35.02|186| #### **Oscillators** | Metric | Value | Implication | |------------------------|-------------|--------------------------------------| | RSI | 31.62 | Oversold (below 30) | | MACD | -0.6 | Bearish divergence (histogram below zero) | | KDJ | 10.78 | Extreme bearish (below 20) | --- ### 📊 **Fundamental Analysis** #### **Valuation Metrics** | Metric | Value | Industry Context | |------------------------|-------------|--------------------------------------| | P/E (TTM) | 142.01 | High premium vs. peers (~25-30) | | P/S (TTM) | 14.39 | Above peers (e.g., BMY: 4.5, JNJ: 5.2) | | Price-to-Book | 23.43 | High premium to tangible assets | #### **Price Target & Consensus** | Metric | Value | Implication | |------------------------|-------------|--------------------------------------| | Avg. Price Target | $40.50 | 15.6% upside from current price ($35.02) | | Consensus Rating | Buy | 75% analysts recommend buying | --- ### 📈 **Recent Developments** 1. **Q2 Earnings Setup**: - Consensus EPS: $0.29 (+700% YoY), Revenue: $146.27M (+99.1% YoY). - **Key Drivers**: Briumvi sales growth (+137% YoY in Q1 2025). - **Risks**: Potential execution misses vs. high market expectations. 2. **Pipeline Progress**: - Subcutaneous Briumvi in Phase 1 trials. - CAR T therapy (Azer-cel) for PPMS in early stages. 3. **Competitive Landscape**: - Roche’s Ocrevus dominates MS market ($7.43B sales in 2024). - TGTX’s Briumvi offers shorter infusion time (1 hour vs. 2-4 hours). --- ### 🚨 **Risk Factors** 1. **Valuation Risk**: High P/E (142.01) and P/S (14.39) vs. peers. 2. **Competition**: Roche’s subcutaneous Ocrevus launch could cannibalize Briumvi sales. 3. **Earnings Pressure**: High expectations for Q2 beat (+700% YoY EPS). --- ### 🎯 **Final Takeaway** **TG Therapeutics (TGTX)** is a **Hold** with **bullish potential** if it breaks above $39.73 resistance. The stock is **overvalued** relative to peers (P/S = 14.39 vs. sector average ~5-7) but offers **high upside** from Briumvi’s growth and pipeline expansion. Monitor **RSI** (oversold at 31.62) and **price action** near $35.10 support for entry opportunities.